MDV 3100

Known as: ASP9785, MDV-3100, MDV3100 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2017
0204020092017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably succumb to the disease. Progression to CRPC… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Androgen receptor (AR) signalling remains critically important in metastatic castration-resistant prostate cancer… (More)
  • table 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
UNLABELLED Castration-resistant prostate cancer (CRPC) is the most aggressive, incurable form of prostate cancer. MDV3100… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Persistent androgen receptor (AR) transcriptional activity underlies resistance to AR-targeted therapy and progression to lethal… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Continued androgen receptor (AR) signaling is an established mechanism underlying castration-resistant prostate cancer (CRPC… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Continued reliance on the androgen receptor (AR) is now understood as a core mechanism in castration-resistant prostate cancer… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Prostate cancer progression can be associated with androgen receptor (AR) mutations acquired following treatment with castration… (More)
  • figure 1
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Androgen receptor (AR) splice variants lacking the ligand binding domain (ARVs), originally isolated from prostate cancer cell… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND MDV3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?